Cipla vs Apollohosp Q3 FY24

Cipla delivered a strong Q3 FY24 with revenue of INR 6,544 crore (+14% YoY) and EBITDA margin of 26.3%, driven by market-leading growth in India (+12%), an all-time high US revenue of $230 million (+18% YoY), and robust SAGA performance. The India chronic portfolio outpaced the market, while US growth was fueled by seasonality and Lanreotide (20% market share). Management guided FY24 EBITDA margins at the higher end of 23-24% and expects Q4 seasonality weakness. Key pipeline updates include Symbicort filing, Advair filing by mid-FY25, and four peptide launches in FY25. Risks include US FDA observations at Indore (warning letter) and Goa facilities, potential pricing compression in US generics, and delays in Abraxane launch.

Guidance read

FY24 EBITDA margin at higher end of 23-24%: Full-year EBITDA margin trending at the higher end of the previously guided range of 23-24%. Advair filing by mid-FY25: Advair generic expected to be filed by mid-FY25 from an alternate site, with approval likely by end of next fiscal. Four peptide launches in FY25: Four peptide launches planned in FY25, with one asset awaiting approval expected in Q1 FY25. Symbicort filing completed: Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.

Risk read

Key risks include US FDA warning letter at Indore facility — Indore facility received a warning letter citing Albuterol complaints; resolution timeline uncertain and may impact future approvals.; Goa facility re-inspection uncertainty — Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.; US generic pricing compression — Pricing environment in US generics is in a downcycle; compression expected to move from 4-6% to 6-8% within a year.; Abraxane launch delay — Abraxane launch via third-party transfer is taking longer; fastest route is from Goa facility, which is subject to FDA inspection..

Promise ledger

Of 3 tracked promises, management 0 met, 0 close, 3 missed.

Apollo Hospitals reported a strong Q3 FY24 with consolidated revenue of INR 4,851 crore (+14% YoY) and EBITDA of INR 614 crore (+21% YoY). PAT surged 56% YoY to INR 245 crore, driven by robust healthcare services growth (12% YoY) and a significant milestone: Apollo HealthCo achieved break-even a quarter early. Hospital occupancy stood at 66%, with ARPOB up 10% to INR 56,368. Management guided for 200 bps margin improvement in healthcare services over the next few quarters, supported by volume growth and cost rationalization. The 24/7 digital platform is expected to break even in 6-8 quarters, with new revenue streams like insurance distribution and digital therapeutics. A 2,000-bed expansion plan over four years is underway. Key risk: new bed additions may temporarily pressure margins if ramp-up is slower than expected.

Guidance read

Healthcare services revenue growth of 15% for FY24: Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%. 200 bps margin improvement in healthcare services over next few quarters: Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization. Apollo 24/7 break-even in 6-8 quarters: Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics. 2,000 beds over four years at INR 3,000 crore capex: Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.

Risk read

Key risks include Margin pressure from new bed additions — New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.; Seasonality and one-off events impacting growth — Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.; Slowdown in 24/7 daily active users — Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.; Regulatory risk from kidney racket allegations — Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.